All In Biotech

Drug Trial Radar · NCT07086976

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Period and Long-term Extension to Assess the Efficacy and Safety of Rilzabrutinib in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Aug 18, 2025

Primary completion

May 31, 2028

Study completion Dec 26, 2029

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jul 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approximately 90 male and female participants ≥ 18 years of age with a confirmed diagnosis of primary wAIHA. Following a 4-week screening period, eligible participants will be randomized in a 2:1 ratio to receive rilzabrutinib or placebo in primary analysis period (PAP) for a duration of up to 24 weeks. All participants who completed PAP will then continue in open-label period (OLP) to receive rilzabrutinib for a duration of 28 weeks. Upon the completion of OLP, only participants who demonstrate Hb increase during the last 8 weeks of OLP per specified criteria in the protocol will be eligible to continue in long-term extension (LTE) of the study. The duration of the LTE period will be from the first-participant-in (FPI)-LTE until the last participant completes 52 weeks in LTE. The safety follow-up period of this study following treatment completion or discontinuation will be 2 weeks.

Conditions

  • Autoimmune Haemolytic Anaemia

Interventions

  • rilzabrutinibDrug

    Pharmaceutical form:tablet-Route of administration:oral

  • placeboDrug

    Pharmaceutical form:tablet-Route of administration:oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving DHR. DHR is defined as an increase of Hb by ≥2 g/dL from baseline on at least two thirds of evaluable scheduled visits between Week 12 and Week 24 (inclusive) in the PAPTime frame: By Week 24

Locations

105 sites in 18 countries. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona - Phoenix- Site Number : 8400032

    Phoenix, Arizona · Recruiting

  • Noble Clinical Research- Site Number : 8400003

    Tucson, Arizona · Completed

  • City of Hope Comprehensive Cancer Center- Site Number : 8400023

    Duarte, California · Recruiting

  • Cancer and Blood Specialty Clinic - Los Alamitos- Site Number : 8400038

    Los Alamitos, California · Recruiting

  • USC Norris Comprehensive Cancer Center- Site Number : 8400007

    Los Angeles, California · Recruiting

  • Stanford University Medical Center- Site Number : 8400026

    Stanford, California · Recruiting

  • Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center- Site Number : 8400006

    Torrance, California · Recruiting

  • Yale University School of Medicine- Site Number : 8400027

    New Haven, Connecticut · Recruiting

  • MedStar Georgetown University Hospital- Site Number : 8400004

    Washington D.C., District of Columbia · Recruiting

  • Hialeah Hospital- Site Number : 8400009

    Hialeah, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center- Site Number : 8400031

    Miami, Florida · Recruiting

  • University Hospital and Medical Center- Site Number : 8400005

    Tamarac, Florida · Recruiting

  • Tulane University School of Medicine- Site Number : 8400037

    New Orleans, Louisiana · Recruiting

  • Massachusetts General Hospital- Site Number : 8400001

    Boston, Massachusetts · Recruiting

  • Beth Israel Deaconess Medical Center - Boston- Site Number : 8400034

    Boston, Massachusetts · Recruiting

  • University of Michigan Health System - Ann Arbor- Site Number : 8400014

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Hospital- Site Number : 8400012

    Detroit, Michigan · Recruiting

  • Mayo Clinic in Rochester - Minnesota- Site Number : 8400008

    Rochester, Minnesota · Recruiting

  • Montefiore Medical Center - Einstein Campus- Site Number : 8400011

    The Bronx, New York · Recruiting

  • Cleveland Clinic - Cleveland- Site Number : 8400029

    Cleveland, Ohio · Recruiting

  • Ohio State University Hospital East- Site Number : 8400020

    Columbus, Ohio · Recruiting

  • Fox Chase Cancer Center - Philadelphia- Site Number : 8400019

    Philadelphia, Pennsylvania · Recruiting

  • Brown University Health - Rhode Island Hospital- Site Number : 8400028

    Providence, Rhode Island · Recruiting

  • Baptist Memorial Hospital- Site Number : 8400018

    Memphis, Tennessee · Recruiting

  • UT Health - San Antonio- Site Number : 8400015

    San Antonio, Texas · Recruiting

  • Fred Hutchinson Cancer Center- Site Number : 8400016

    Seattle, Washington · Recruiting

  • Gundersen Health System - La Crosse Medical Center- Site Number : 8400033

    La Crosse, Wisconsin · Recruiting

  • Investigational Site Number : 0320003

    Buenos Aires, Argentina · Recruiting

  • Investigational Site Number : 0320002

    Buenos Aires, Argentina · Recruiting

  • Investigational Site Number : 0320001

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Investigational Site Number : 0400001

    Vienna, Austria · Recruiting

  • Investigational Site Number : 0400002

    Vienna, Austria · Recruiting

  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760003

    São Paulo, Brazil · Recruiting

  • Hemoes - Centro Estadual de Hemoterapia e Hematologia Marcos Daniel Santos- Site Number : 0760002

    Vitória, Espírito Santo, Brazil · Recruiting

  • Universidade Federal de Goias- Site Number : 0760001

    Goiânia, Goiás, Brazil · Recruiting

  • Investigational Site Number : 1560001

    Beijing, China · Recruiting

  • Investigational Site Number : 1560007

    Chengde, China · Recruiting

  • Investigational Site Number : 1560011

    Guangzhou, China · Recruiting

  • Investigational Site Number : 1560005

    Guangzhou, China · Recruiting

  • Investigational Site Number : 1560009

    Hohhot, China · Recruiting

Showing 40 of 105 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.